SCHEMBL15329426

SCHEMBL15329426

CCOC(=O)c1nn(-c2c(F)cc(C(F)(F)F)cc2Cl)c(C)c1[S+]([O-])C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRB3 P28472 8/20 0.48
GABRA2 P47869 6/20 0.48
GABRB2 P47870 6/20 0.48
GABRP O00591 4/20 0.48
GABRD O14764 4/20 0.48
GABRA1 P14867 4/20 0.48
GABRB1 P18505 4/20 0.48
GABRG2 P18507 4/20 0.48
GABRA5 P31644 4/20 0.48
GABRA3 P34903 4/20 0.48
GABRA4 P48169 4/20 0.48
GABRE P78334 4/20 0.48
GABRA6 Q16445 4/20 0.48
GABRG1 Q8N1C3 4/20 0.48
GABRG3 Q99928 4/20 0.48
GABRQ Q9UN88 4/20 0.48
ADORA1 P30542 2/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
RECQL P46063 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15329351 0.87 GABRB3 (0.43) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL15329125 0.86 GABRB3 (0.40) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL7715369 0.85 GABRP (0.62) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL15329104 0.83 GABRB3 (0.50) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL16558042 0.82 GABRB3 (0.52) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL28344742 0.82 GABRB3 (0.48) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL2834331 0.80 GABRB3 (0.49) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL15339720 0.78 GABRB3 (0.49) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL2835863 0.76 GABRB3 (0.43) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL2836888 0.76 GABRB3 (0.53) GABRB3GABRA2GABRB2GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3184510-B1 IMPROVED PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS MERIAL INC (US) 2019-06-12 EP disclosed
EP-3184510-A1 IMPROVED PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS Merial, Inc. (US) 2017-06-28 EP disclosed
EP-2852577-B1 IMPROVED PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS MERIAL INC (US) 2017-03-01 EP disclosed
US-9273007-B2 Processes for the preparation of 1-aryl-5-alkyl pyrazole compounds MERIAL, INC. (US) 2016-03-01 US disclosed
US-9273007-B2 Processes for the preparation of 1-aryl-5-alkyl pyrazole compounds MERIAL, INC. (US) 2016-03-01 US disclosed
US-9273007-B2 Processes for the preparation of 1-aryl-5-alkyl pyrazole compounds MERIAL, INC. (US) 2016-03-01 US disclosed
EP-2852577-A2 IMPROVED PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS Merial Limited (US) 2015-04-01 EP disclosed
US-20150073153-A1 PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS MERIAL LIMITED (US) 2015-03-12 US disclosed
US-20150073153-A1 PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS MERIAL LIMITED (US) 2015-03-12 US disclosed
US-20150073153-A1 PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS MERIAL LIMITED (US) 2015-03-12 US disclosed
US-8937185-B2 Processes for the preparation of 1-aryl-5-alkyl pyrazole compounds MERIAL LIMITED (US) 2015-01-20 US disclosed
US-8937185-B2 Processes for the preparation of 1-aryl-5-alkyl pyrazole compounds MERIAL LIMITED (US) 2015-01-20 US disclosed
US-20130281710-A1 PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS MERIAL LIMITED (US) 2013-10-24 US disclosed
US-20130281710-A1 PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS MERIAL LIMITED (US) 2013-10-24 US disclosed
WO-2013159094-A2 IMPROVED PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS MERIAL LIMITED (US) 2013-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150073153-A1 PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS SULT1A1, CYP1B1, CYP2F1 GABRB3 829/4885GABRA2 1401/4885GABRB2 1011/4885
US-20130281710-A1 PROCESSES FOR THE PREPARATION OF 1-ARYL-5-ALKYL PYRAZOLE COMPOUNDS SULT1A1, CYP1B1, CYP2F1 GABRB3 829/4885GABRA2 1401/4885GABRB2 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.